Course Information

Release date: October 17, 2025

Expiration date: January 17, 2026

Estimated time to complete activity: 15 minutes

PROVIDER STATEMENT

Provided by Integrity CE, LLC.

DISCLOSURE OF COMMERCIAL SUPPORT

Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

This activity is supported by an independent medical education grant from Merck Sharp & Dohme LLC.

PROGRAM OVERVIEW

This activity guides learners through the evolving treatment landscape of advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations. A real-world patient case is used to explore the optimal clinical application of frontline amivantamab plus chemotherapy and examine the role of emerging small-molecule tyrosine kinase inhibitors. Participants will integrate current guideline recommendations and pivotal clinical trial data to make informed, personalized treatment decisions for patients with this challenging NSCLC subtype.

Learning Objectives

TARGET AUDIENCE

This educational activity has been designed to meet the needs of medical and surgical oncologists, pulmonologists, physician assistants, nurse practitioners, nurses, and other healthcare providers involved in treatment and management of patients with lung cancers.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

Integrate genomic, immunogenic, and proteomic aberration assessments to guide treatment decisions
Select personalized therapeutic regimens consistent with current evidence and best practices
Implement supportive care strategies to mitigate and manage unique toxicities associated with recently approved and emerging therapies

Faculty Information and Disclosures

FACULTY

	Melina Marmarelis MD, MSCE Assistant Professor Physician Lead, Airways Research Program Medical Director, Mesothelioma Program Co-Director, Molecular Tumor Board University of Pennsylvania Philadelphia, Pennsylvania
	Benjamin Bleiberg, MD Hematology/Oncology Fellow University of Pennsylvania Philadelphia, Pennsylvania

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Melina Marmarelis MD, MSCE

Consultant: Astra Zeneca, Bayer, Blueprint Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Ikena, Janssen, Neuvogen, Novocure, Regeneron, Takeda

Honoraria: Thermo Fisher

Researching Funding from Institution: AstraZeneca, Eli Lilly, Genentech, Merck

Stock: Johnson & Johnson

Benjamin Bleiberg, MD

Consultant, Steering Committee Member: Janssen

Honoraria: MJH Life Sciences

The Integrity CE, LLC planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

Accreditation Information

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of October 17, 2025 through January 17, 2026, participants must:

Read the learning objectives and faculty disclosures
Complete the pretest
Study the educational activity
Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 50% or better and a completed activity evaluation form. A statement of credit will be issued by our system and immediately available to download following your completion of the posttest and evaluation.

ACCREDITATION STATEMENT

Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity CE, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimers and Technical Requirements

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity CE, LLC, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Internet: Stable connection
Operating Systems: Windows 10/macOS 10.14 or later recommended
Web Browser: Latest versions of Google Chrome, Microsoft Edge, or Safari recommended (other modern browsers also supported)
Plug-ins: No plug-ins required

For optimal performance and security, ensure your browser is up to date and avoid using unsupported or outdated versions.

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Uncommon EGFR Mutations: Targeting Exon 20 in Advanced NSCLC